Murban futures contract continues to grow in stature, trading alongside Brent and WTI
The all-cash deal has been challenged by Franklin Advisers and Templeton Assets Management, which own a combined nine percent stake in Taro, on grounds it could hurt minority shareholders, Sun told the Mumbai stock exchange in a statement.
“Sun Pharma believes the proceedings initiated by Franklin Advisers and Templeton are without merit and detrimental to the best interests of shareholders and Taro,” the statement said.
The minority shareholders have filed a case in the Israeli capital Tel-Aviv, seeking a stay on the deal, the statement said.
Sun makes specialty drugs while Taro, which makes over 90 percent of its sales in North America, has a strong franchise in dermatology and topical products.
“We intend to build on Taro’s expertise in dermatology and pediatrics along with specialty and generic pharmaceuticals and over-the-counter products,” Sun Pharma chairman Dilip Shanghvi said.
Sun will fund the all-cash deal through internal accruals and money from a previous convertible bond offering, the company said.
“This is all-cash deal, subject to regulatory clearances,” Sun said.
Taro’s equity is valued at 230 million dollars or 7.7 dollar per share, a 27 percent premium to its Friday’s close of 6.1 dollars, while its debt totals 224 million dollars.
Sun’s shares rose 37.3 rupees or 3.69 percent to 1,050 after the announcement, outpacing the broader market.
Murban futures contract continues to grow in stature, trading alongside Brent and WTI
Project will leverage the latest technologies and AI tools to lower emissions and drive efficiency
Pact aims to support businesses and investment ecosystem
Investors last year were happy to pay up for the megacaps
Marketers and advertisers can now finetune and personalise their campaigns
Decision is going to allow for the free flow of capital into the country
Middle East witnessed a 6.2% increase in the super-wealthy last year
Transaction gained significant market interest